Marty Whitman
Third Avenue Management
Third Avenue Management Supernus Pharmaceuticals Inc stake
total: 405
Third Avenue Management SUPN trades
- Total transactions:
- 7
- New positions:
- 1
- Added:
- 5
- Reduced:
- 1
- Held since:
- 2022 Q2
- Held for:
- 17 quarters
- Latest activity:
- 2026 Q1
According to 2026 Q2 report, Third Avenue Management holds 152,724 Supernus Pharmaceuticals Inc (SUPN) shares with a market value of roughly $7.10M accounting for 1.14% of the overall portfolio. To date, the estimated cost basis is nearly $28.77 for "buy" trades and estimated average "sell" price is $51.69. Third Avenue Management first purchased SUPN in 2022 Q2, initially acquiring 2,460 shares. Since the initial investment in Supernus Pharmaceuticals Inc (SUPN), Third Avenue Management has made 6 more transactions.
When did Third Avenue Management buy Supernus Pharmaceuticals Inc (SUPN)?
Third Avenue Management first invested in Supernus Pharmaceuticals Inc (SUPN) in 2022 Q2 at the reported quarter-end price of $29.27 per share.
What's the cost basis of Third Avenue Management's SUPN stake?
The estimated cost basis for Supernus Pharmaceuticals Inc (SUPN) stake is around $28.77 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $28.77
- Weighted AVG sell price:
- $51.69
Third Avenue Management's historical trades in Supernus Pharmaceuticals Inc
7 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q1
|
1.28%
|
152,724
|
$51.69
|
$7,894,304
|
-19.40% (-36,769)
|
-0.35%
|
|
2024 Q3
|
0.97%
|
189,493
|
$31.18
|
$5,908,392
|
+0.20% (+375)
|
+0%
|
|
2024 Q2
|
0.87%
|
189,118
|
$26.75
|
$5,058,907
|
+18.41% (+29,401)
|
+0.13%
|
|
2023 Q4
|
0.76%
|
159,717
|
$28.94
|
$4,622,210
|
+37.04% (+43,168)
|
+0.21%
|
|
2023 Q3
|
0.55%
|
116,549
|
$28.08
|
$3,272,696
|
+73.79% (+49,487)
|
+0.23%
|
|
2023 Q2
|
0.33%
|
67,062
|
$30.06
|
$2,015,884
|
+2,626.10% (+64,602)
|
+0.32%
|
|
2022 Q2
|
0.01%
|
2,460
|
$29.27
|
$72,000
|
new
|
+0.01%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.